{"data":{"id":"us-nh/rsa-318-b-1-c","jurisdiction":"us-nh","citation":"RSA 318-B:1-c","heading":"Flunitrazepam.","body":"I. The legislature intends that the provisions of paragraph III of this section shall remain in effect until such time as flunitrazepam is scheduled by the commissioner of the department of human services in accordance with and pursuant to RSA 318-B.\nII. The legislature finds that flunitrazepam, marketed under the trade name rohypnol, which has a sedative, hypnotic, and amnesiac effect, has no acceptable medical uses in the United States and carries a high potential for abuse. Therefore, flunitrazepam meets the criteria for placement on schedule I of controlled drugs.\nIII. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of health and human services, flunitrazepam shall be scheduled as a schedule I controlled drug.","path":["Title XXX: OCCUPATIONS AND PROFESSIONS","Chapter 318-B: CONTROLLED DRUG ACT"],"source_url":"https://gc.nh.gov/rsa/html/XXX/318-B/318-B-1-c.htm","current_through":"2025 regular legislative session, or December 2025","vintage":"","retrieved_at":"2026-09-05T15:00:32Z","sha256":"e56170411695b52541294ac425a780e5e97dc4ab1cec2a3a2b9caa0bfc1aecfb","source_id":"us-nh","stale":false,"prev":"us-nh/rsa-318-b-1-b","next":"us-nh/rsa-318-b-2"},"notice":"GroundRules: Original legal text. Not legal advice."}